Diabetes Mellitus and Heart Failure
The coexistence of diabetes mellitus (DM) and heart failure (HF) is frequent and is associated with a higher risk of hospitalization for HF and all-cause and cardiovascular mortality. It has been estimated that millions of people are affected by HF and DM, and the prevalence of both conditions has i...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/10/1698 |
| _version_ | 1797472144301490176 |
|---|---|
| author | Wun-Zhih Siao Yong-Hsin Chen Chin-Feng Tsai Chun-Ming Lee Gwo-Ping Jong |
| author_facet | Wun-Zhih Siao Yong-Hsin Chen Chin-Feng Tsai Chun-Ming Lee Gwo-Ping Jong |
| author_sort | Wun-Zhih Siao |
| collection | DOAJ |
| description | The coexistence of diabetes mellitus (DM) and heart failure (HF) is frequent and is associated with a higher risk of hospitalization for HF and all-cause and cardiovascular mortality. It has been estimated that millions of people are affected by HF and DM, and the prevalence of both conditions has increased over time. Concomitant HF and diabetes confer a worse prognosis than each alone; therefore, managing DM care is critical for preventing HF. This article reviews the prevalence of HF and diabetes and the correlated prognosis as well as provides a basic understanding of diabetic cardiomyopathy, including its pathophysiology, focusing on the relationship between DM and HF with a preserved ejection fraction and summarizes the potential aldosterone and the mineralocorticoid receptor antagonists approaches for managing heart failure and DM. Sodium–glucose cotransporter 2 inhibitors (SGLT2Is) are an emerging class of glucose-lowering drugs, and the role of SGLT2Is in DM patients with HF was reviewed to establish updated and comprehensive concepts for improving optimal medical care in clinical practice. |
| first_indexed | 2024-03-09T19:57:58Z |
| format | Article |
| id | doaj.art-5feab8aa8c89470cb9cbf0437cdcb375 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T19:57:58Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-5feab8aa8c89470cb9cbf0437cdcb3752023-11-24T00:50:33ZengMDPI AGJournal of Personalized Medicine2075-44262022-10-011210169810.3390/jpm12101698Diabetes Mellitus and Heart FailureWun-Zhih Siao0Yong-Hsin Chen1Chin-Feng Tsai2Chun-Ming Lee3Gwo-Ping Jong4Division of Cardiology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40201, TaiwanDepartment of Public Health, Chung Shan Medical University, Taichung 40201, TaiwanDivision of Cardiology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40201, TaiwanDepartment of Internal Medicine, St. Joseph’s Hospital, Yunlin County 63201, TaiwanDivision of Cardiology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40201, TaiwanThe coexistence of diabetes mellitus (DM) and heart failure (HF) is frequent and is associated with a higher risk of hospitalization for HF and all-cause and cardiovascular mortality. It has been estimated that millions of people are affected by HF and DM, and the prevalence of both conditions has increased over time. Concomitant HF and diabetes confer a worse prognosis than each alone; therefore, managing DM care is critical for preventing HF. This article reviews the prevalence of HF and diabetes and the correlated prognosis as well as provides a basic understanding of diabetic cardiomyopathy, including its pathophysiology, focusing on the relationship between DM and HF with a preserved ejection fraction and summarizes the potential aldosterone and the mineralocorticoid receptor antagonists approaches for managing heart failure and DM. Sodium–glucose cotransporter 2 inhibitors (SGLT2Is) are an emerging class of glucose-lowering drugs, and the role of SGLT2Is in DM patients with HF was reviewed to establish updated and comprehensive concepts for improving optimal medical care in clinical practice.https://www.mdpi.com/2075-4426/12/10/1698diabetes mellitusheart failuresodium–glucose cotransporter 2 inhibitorsreduced ejection fractionpreserved ejection fraction |
| spellingShingle | Wun-Zhih Siao Yong-Hsin Chen Chin-Feng Tsai Chun-Ming Lee Gwo-Ping Jong Diabetes Mellitus and Heart Failure Journal of Personalized Medicine diabetes mellitus heart failure sodium–glucose cotransporter 2 inhibitors reduced ejection fraction preserved ejection fraction |
| title | Diabetes Mellitus and Heart Failure |
| title_full | Diabetes Mellitus and Heart Failure |
| title_fullStr | Diabetes Mellitus and Heart Failure |
| title_full_unstemmed | Diabetes Mellitus and Heart Failure |
| title_short | Diabetes Mellitus and Heart Failure |
| title_sort | diabetes mellitus and heart failure |
| topic | diabetes mellitus heart failure sodium–glucose cotransporter 2 inhibitors reduced ejection fraction preserved ejection fraction |
| url | https://www.mdpi.com/2075-4426/12/10/1698 |
| work_keys_str_mv | AT wunzhihsiao diabetesmellitusandheartfailure AT yonghsinchen diabetesmellitusandheartfailure AT chinfengtsai diabetesmellitusandheartfailure AT chunminglee diabetesmellitusandheartfailure AT gwopingjong diabetesmellitusandheartfailure |